DjamgaMind: Audio Intelligence for the C-Suite (Daily AI News, Energy, Healthcare, Finance)
Full-Stack AI Intelligence. Zero Noise.The definitive audio briefing for the C-Suite and AI Architects. From Daily News and Strategic Deep Dives to high-density Industrial & Regulatory Intelligence—decoded at the speed of the AI era. . 👉 Start your specialized audio briefing today at Djamgamind.com
AI Jobs and Career
I wanted to share an exciting opportunity for those of you looking to advance your careers in the AI space. You know how rapidly the landscape is evolving, and finding the right fit can be a challenge. That's why I'm excited about Mercor – they're a platform specifically designed to connect top-tier AI talent with leading companies. Whether you're a data scientist, machine learning engineer, or something else entirely, Mercor can help you find your next big role. If you're ready to take the next step in your AI career, check them out through my referral link: https://work.mercor.com/?referralCode=82d5f4e3-e1a3-4064-963f-c197bb2c8db1. It's a fantastic resource, and I encourage you to explore the opportunities they have available.
- Full Stack Engineer [$150K-$220K]
- Software Engineer, Tooling & AI Workflow, Contract [$90/hour]
- DevOps Engineer, India, Contract [$90/hour]
- More AI Jobs Opportunitieshere
| Job Title | Status | Pay |
|---|---|---|
| Full-Stack Engineer | Strong match, Full-time | $150K - $220K / year |
| Developer Experience and Productivity Engineer | Pre-qualified, Full-time | $160K - $300K / year |
| Software Engineer - Tooling & AI Workflows (Contract) | Contract | $90 / hour |
| DevOps Engineer (India) | Full-time | $20K - $50K / year |
| Senior Full-Stack Engineer | Full-time | $2.8K - $4K / week |
| Enterprise IT & Cloud Domain Expert - India | Contract | $20 - $30 / hour |
| Senior Software Engineer | Contract | $100 - $200 / hour |
| Senior Software Engineer | Pre-qualified, Full-time | $150K - $300K / year |
| Senior Full-Stack Engineer: Latin America | Full-time | $1.6K - $2.1K / week |
| Software Engineering Expert | Contract | $50 - $150 / hour |
| Generalist Video Annotators | Contract | $45 / hour |
| Generalist Writing Expert | Contract | $45 / hour |
| Editors, Fact Checkers, & Data Quality Reviewers | Contract | $50 - $60 / hour |
| Multilingual Expert | Contract | $54 / hour |
| Mathematics Expert (PhD) | Contract | $60 - $80 / hour |
| Software Engineer - India | Contract | $20 - $45 / hour |
| Physics Expert (PhD) | Contract | $60 - $80 / hour |
| Finance Expert | Contract | $150 / hour |
| Designers | Contract | $50 - $70 / hour |
| Chemistry Expert (PhD) | Contract | $60 - $80 / hour |
Longevity gene therapy and AI – What is on the horizon?
Gene therapy holds promise for extending human lifespan and enhancing healthspan by targeting genes associated with aging processes. Longevity gene therapy, particularly interventions focusing on genes like TERT (telomerase reverse transcriptase), Klotho, and Myostatin, is at the forefront of experimental research. Companies such as Bioviva, Libella, and Minicircle are pioneering these interventions, albeit with varying degrees of transparency and scientific rigor.
TERT, Klotho, and Myostatin in Longevity
- TERT: The TERT gene encodes for an enzyme essential in telomere maintenance, which is linked to cellular aging. Overexpression of TERT in model organisms has shown potential in lengthening telomeres, potentially delaying aging.
- Klotho: This gene plays a crucial role in regulating aging and lifespan. Klotho protein has been associated with multiple protective effects against age-related diseases.
- Myostatin: Known for its role in regulating muscle growth, inhibiting Myostatin can result in increased muscle mass and strength, which could counteract some age-related physical decline.
The Experimental Nature of Longevity Gene Therapy
The application of gene therapy for longevity remains largely experimental. Most available data come from preclinical studies, primarily in animal models. Human data are scarce, raising questions about efficacy, safety, and potential long-term effects. The ethical implications of these experimental treatments, especially in the absence of robust data, are significant, touching on issues of access, consent, and potential unforeseen consequences.
Companies Offering Longevity Gene Therapy
- Bioviva: Notably involved in this field, Bioviva has been vocal about its endeavors in gene therapy for aging. While they have published some data from mouse studies, human data remain limited.
- Libella and Minicircle: These companies also offer longevity gene therapies but face similar challenges in providing comprehensive human data to back their claims.
Industry Perspective vs. Public Discourse
The discourse around longevity gene therapy is predominantly shaped by those within the industry, such as Liz Parrish of Bioviva and Bryan Johnson. While their insights are valuable, they may also be biased towards promoting their interventions. The lack of widespread discussion on platforms like Reddit and Twitter, especially from independent sources or those outside the industry, points to a need for greater transparency and peer-reviewed research.

Ethical and Regulatory Considerations
The ethical and regulatory landscape for gene therapy is complex, particularly for treatments aimed at non-disease conditions like aging. The experimental status of longevity gene therapies raises significant ethical questions, particularly around informed consent and the potential long-term impacts. Regulatory bodies are tasked with balancing the potential benefits of such innovative treatments against the risks and ethical concerns, requiring a robust framework for clinical trials and approval processes.
Longevity Gene Therapy and AI
Integrating Artificial Intelligence (AI) into longevity gene therapy represents a groundbreaking intersection of biotechnology and computational sciences. AI and machine learning algorithms are increasingly employed to decipher complex biological data, predict the impacts of genetic modifications, and optimize therapy designs. In the context of longevity gene therapy, AI can analyze vast datasets from genomics, proteomics, and metabolomics to identify new therapeutic targets, understand the intricate mechanisms of aging, and predict individual responses to gene therapies. This computational power enables researchers to simulate the effects of gene editing or modulation before actual clinical application, enhancing the precision and safety of therapies. Furthermore, AI-driven platforms facilitate the personalized tailoring of gene therapy interventions, taking into account the unique genetic makeup of each individual, which is crucial for effective and minimally invasive treatment strategies. The synergy between AI and longevity gene therapy accelerates the pace of discovery and development in this field, promising more rapid translation of research findings into clinical applications that could extend human healthspan and lifespan.
AI-Powered Professional Certification Quiz Platform
Web|iOs|Android|Windows
Are you passionate about AI and looking for your next career challenge? In the fast-evolving world of artificial intelligence, connecting with the right opportunities can make all the difference. We're excited to recommend Mercor, a premier platform dedicated to bridging the gap between exceptional AI professionals and innovative companies.
Whether you're seeking roles in machine learning, data science, or other cutting-edge AI fields, Mercor offers a streamlined path to your ideal position. Explore the possibilities and accelerate your AI career by visiting Mercor through our exclusive referral link:
Find Your AI Dream Job on Mercor
Your next big opportunity in AI could be just a click away!
Moving Forward
For longevity gene therapy to advance from experimental to accepted medical practice, several key developments are needed:
- Robust Human Clinical Trials: Rigorous, peer-reviewed clinical trials involving human participants are essential to establish the safety and efficacy of gene therapies for longevity.
- Transparency and Peer Review: Open sharing of data and peer-reviewed publication of results can help build credibility and foster a more informed public discourse.
- Ethical and Regulatory Frameworks: Developing clear ethical guidelines and regulatory pathways for these therapies will be crucial in ensuring they are deployed responsibly.
The future of longevity gene therapy is fraught with challenges but also holds immense promise. As the field evolves, a multidisciplinary approach involving scientists, ethicists, regulators, and the public will be crucial in realizing its potential in a responsible and beneficial manner.
AI- Powered Jobs Interview Warmup For Job Seekers

⚽️Comparative Analysis: Top Calgary Amateur Soccer Clubs – Outdoor 2025 Season (Kids' Programs by Age Group)
Longevity gene therapy and AI: Annex
What are the top 10 most promising potential longevity therapies being researched?
I think the idea of treating aging as a disease that’s treatable and preventable in some ways is a really necessary focus. The OP works with some of the world’s top researchers using HBOT as part of that process to increase oxygen in the blood and open new pathways in the brain to address cognitive decline and increase HealthSpan (vs. just lifespan). Pretty cool stuff!
HBOT in longevity research stands for “hyperbaric oxygen therapy.” It has been the subject of research for its potential effects on healthy aging. Several studies have shown that HBOT can target aging hallmarks, including telomere shortening and senescent cell accumulation, at the cellular level. For example, a prospective trial found that HBOT can significantly modulate the pathophysiology of skin aging in a healthy aging population, indicating effects such as angiogenesis and senescent cell clearance. Additionally, research has demonstrated that HBOT may induce significant senolytic effects, including increasing telomere length and decreasing senescent cell accumulation in aging adults. The potential of HBOT in healthy aging and its implications for longevity are still being explored, and further research is needed to fully understand its effects and potential applications.
AI Jobs and Career
And before we wrap up today's AI news, I wanted to share an exciting opportunity for those of you looking to advance your careers in the AI space. You know how rapidly the landscape is evolving, and finding the right fit can be a challenge. That's why I'm excited about Mercor – they're a platform specifically designed to connect top-tier AI talent with leading companies. Whether you're a data scientist, machine learning engineer, or something else entirely, Mercor can help you find your next big role. If you're ready to take the next step in your AI career, check them out through my referral link: https://work.mercor.com/?referralCode=82d5f4e3-e1a3-4064-963f-c197bb2c8db1. It's a fantastic resource, and I encourage you to explore the opportunities they have available.
2- Are they also looking into HBOT as a treatment for erectile dysfunction?
Definitely! Dr. Shai Efrati has been doing research around that and had a study published in the Journal of Sexual Medicine. Dr. Efrati and his team found that 80% of men “reported improved erections” after HBOT therapy: https://www.nature.com/articles/s41443-018-0023-9
3- I think cellular reprogramming seems to be one of the most promising approaches https://www.lifespan.io/topic/yamanaka-factors/
Invest in your future today by enrolling in this Azure Fundamentals - Pass the Azure Fundamentals Exam with Ease: Master the AZ-900 Certification with the Comprehensive Exam Preparation Guide!
- AWS Certified AI Practitioner (AIF-C01): Conquer the AWS Certified AI Practitioner exam with our AI and Machine Learning For Dummies test prep. Master fundamental AI concepts, AWS AI services, and ethical considerations.
- Azure AI Fundamentals: Ace the Azure AI Fundamentals exam with our comprehensive test prep. Learn the basics of AI, Azure AI services, and their applications.
- Google Cloud Professional Machine Learning Engineer: Nail the Google Professional Machine Learning Engineer exam with our expert-designed test prep. Deepen your understanding of ML algorithms, models, and deployment strategies.
- AWS Certified Machine Learning Specialty: Dominate the AWS Certified Machine Learning Specialty exam with our targeted test prep. Master advanced ML techniques, AWS ML services, and practical applications.
- AWS Certified Data Engineer Associate (DEA-C01): Set yourself up for promotion, get a better job or Increase your salary by Acing the AWS DEA-C01 Certification.
4-Next-gen senolytics (eg, Rubedo, Oisin, Deciduous).
Cellular rejuvenation aka partial reprogramming (as someone else already said) but not just by Yamanaka (OSKM) factors or cocktail variants but also by other novel Yamanaka-factor alternatives.
Stem cell secretions.
Treatments for aging extra-cellular matrix (ECM).
5- Rapamycin is the most promising short term.
I see a lot of people saying reprogramming, and I think the idea is promising but as someone who worked on reprogramming cells in vitro I can tell you that any proof of concepts in vivo large animal models is far aways.
6- Blood focused therapies ( dilution, plasma refactoring, e5, exosomes) perhaps look at yuvan research.
7- I think plasmapheresis is a technology most likely to be proven beneficial in the near term and also a technology that can be scaled and offered for reasonable prices.
8- Bioelectricity, if we succeed in interpreting the code of electrical signals By which cells communicate , we can control any tissue growth and development including organs regeneration
9- Gene therapy and reprogramming will blow the lid off the maximum lifespan. Turning longevity genes on/expressing proteins that repair cellular damage and reversing epigenetic changes that occur with aging.
10- I don’t think anything currently being researched (that we know of) has the potential to take us to immortality. That’ll likely end up requiring some pretty sophisticated nanotechnology. However, the important part isn’t getting to immortality, but getting to LEV. In that respect, I’d say senolytics and stem cell treatments are both looking pretty promising. (And can likely achieve more in combination than on their own.)
11- Spiroligomers to remove glucosepane from the ECM.
12- Yuvan Research. Look up the recent paper they have with Steve Horvath on porcine plasma fractions.
13- This OP thinks most of the therapies being researched will end up having insignificant effects. The only thing that looks promising to me is new tissue grown from injected stem cells or outright organ replacement. Nothing else will address DNA damage, which results in gene loss, disregulation of gene expression, and loss of suppression of transposable elements.
14- A couple that haven’t been mentioned:
Cancer:
The killer T-cells that target MR-1 and seem to be able to find and kill all common cancer types.
Also Maia Biotech’s THIO (“WILT 2.0”)
Mitochondria: Mitochondrial infusion that lasts or the allotopic expression of the remaining proteins SENS is working on.
15- Look for first updates coming from altos labs.
Altos Labs is a biotechnology research company focused on unraveling the deep biology of cell rejuvenation to reverse disease and develop life extension therapies that can halt or reverse the human aging process. The company’s goal is to increase the “healthspan” of humans, with longevity extension being an “accidental consequence” of their work. Altos Labs is dedicated to restoring cell health and resilience through cell rejuvenation to reverse disease, injury, and disabilities that can occur throughout life. The company is working on specialized cell therapies based on induced pluripotent stem cells to achieve these objectives. Altos Labs is known for its atypical focus on basic research without immediate prospects of a commercially viable product, and it has attracted significant investment, including a $3 billion funding round in January 2022. The company’s research is based on the fundamental biology of cell rejuvenation, aiming to understand and harness the ability of cells to resist stressors that give rise to disease, particularly in the context of aging.
16– not so much a “therapy” but I think research into growing human organs may be very promising long term. Being able to get organ transplants made from your own cells means zero rejection issues and no limitations of supply for transplants. Near term drugs like rampamycin show good potential for slowing the aging process and are in human trials.
What is biological reprogramming technology?
Biological reprogramming technology involves the process of converting specialized cells into a pluripotent state, which can then be directed to become a different cell type. This technology has significant implications for regenerative medicine, disease modeling, and drug discovery. It is based on the concept that a cell’s identity is defined by the gene regulatory networks that are active in the cell, and these networks can be controlled by transcription factors. Reprogramming can be achieved through various methods, including the introduction of exogenous factors such as transcription factors. The process of reprogramming involves the erasure and remodeling of epigenetic marks, such as DNA methylation, to reset the cell’s epigenetic memory, allowing it to be directed to different cell fates. This technology has the potential to create new cells for regenerative medicine and to provide insights into the fundamental basis of cell identity and disease.
See also
- Gene Therapy Basics for foundational understanding of gene therapy techniques and applications.
- [Aging and Longevity Research]
- Bryan Johnson, a 45-year-old biotech founder, hopes to rewind the clock of his body a few decades through a program he started, called Project Blueprint.
Links to external Longevity-related sites
Outline of Life Extension on Wikipedia
Index of life extension related Wikipedia articles
Accelerate cure for Alzheimers
Aging in Motion
Aging Matters
Aging Portfolio
Alliance for Aging Research
Alliance for Regenerative Medicine
American Academy of Anti-Aging Medicine
American Aging Association
American Federation for Aging Research
American Society on Aging
Blue Zones – /r/BlueZones
Brain Preservation Foundation
British Society for Research on Aging
Calico Labs
Caloric Restriction Society
Church of Perpetual Life
Coalition for Radical Life Extension
Cohbar
Dog Aging Project
ELPI Foundation for Indefinite Lifespan
Fight Aging! Blog
Found My Fitness
Friends of NIA
Gerontology Wiki
Geroscience.com
Global Healthspan Policy Institute
Health Extension
Healthspan Campaign
HEALES
Humanity+ magazine
Humanity+ wiki
International Cell Senescence Association
International Longevity Alliance
International Longevity Centre Global Alliance
International Society on Aging and Disease
Juvena Therapeutics
Leucadia Therapeutics
LEVF
Life Extension Advocacy Foundation
Life Extension Foundation
Lifeboat Foundation
Lifespan.io
Longevity History
Longevity Vision Fund
LongLongLife
Loyal for Dogs Lysoclear
MDI Biological Laboratory
Methuselah Foundation
Metrobiotech
New Organ Alliance
Nuchido
Oisin Biotechnologies
Organ Preservation Alliance
Palo Alto Longevity Prize
Rejuvenaction Blog
Rubedo Life Sciences
Samumed
Senolytx
SENS
Stealth BioTherapeutics
The War On Aging
Unity Biotechnologies
Water Bear Lair
Good Informational Sites:
Programmed Aging Info
Senescence Info
Experimental Gerontology Journal
Mechanisms of Ageing and Development Journal
Schools and Academic Institutions:
Where to do a PhD on aging – a list of labs
Alabama Research Institute on Aging
UT Barshop Institute
Biogerontology Research Foundation
Buck Institute
Columbia Aging Center
Gerontology Research Group
Huffington Center on Aging
Institute for Aging Research – Harvard
Iowa State University Gerontology
Josh Mitteldorf
Longevity Consortium
Max Planck Institute for Biology of Aging – Germany
MIT Agelab
National Institute on Aging
Paul F. Glenn Center for Aging Research – University of Michigan
PennState Center for Healthy Aging
Princeton Longevity Center
Regenerative Sciences Institute
Kogod Center on Aging – Mayo clinic
Salk Institute
Stanford Center on Longevity
Stanford Brunet Lab
Supercenterian Research Foundation
Texas A&M Center for translational research on aging
Gerontological Society of America
Tufts Human Nutrition and Aging Research
UAMS Donald Reynolds Center on Aging
UCLA Longevity Center
UCSF Memory and Aging Center
UIC Center for research on health and aging
University of Iowa Center on Aging
University of Maryland Center for research on aging
University of Washington Biology of Aging
USC School of Gerontology
Wake Forest Institute of Regenerative Medicine
Yale Center for Research on Aging
- Why are Al "assistants" from Apple, Samsung and Amazon so incompetent compared to the current standard of Al?by /u/SallyYess (Artificial Intelligence) on May 16, 2026 at 2:11 am
I cant even ask Alexa to set 2 alarms at the same time without causing confusion? Why does it seem so stupid compared to any AI I could access in Google? EXAMPLE: Im a deep sleeper so I set multiple alarms, i tried asking alexa "set an alarm for 10am and 10.30am" but no she just answers to one... with the current standard of AI why do these mainstream AI devices seem so behind? submitted by /u/SallyYess [link] [comments]
- Gemini mixed up answer and returns some rules or instructions from google mapsby /u/Consistent-Set-9942 (Artificial Intelligence) on May 16, 2026 at 2:06 am
I asked Gemini if i could visit traverse city in a day. Have a look in the screenshots to see what it replied to me. Seems to be some kind of output from google maps to refine its answer. submitted by /u/Consistent-Set-9942 [link] [comments]
- A sobering tale of AI governanceby /u/Im_Talking (Artificial Intelligence (AI)) on May 16, 2026 at 1:15 am
I think this article/study tells a very sobering tale wrt AI governance. It hints at very fundamental issues which are deeper than what proper engineering can solve with contingent issues. This post, along with the one I wrote a few days ago here regarding Turing completeness, are my thoughts as to the walls that AI governance has no hope of scaling. It's a delusion. In our social realm as subjective creatures we have governance in the form of laws, yet that is still not enough, since the State has to prove how your particular scenario violates that particular law. We have laws, yet require judicial courts to prove the law subjectively applies in that situation. Where is the associated path wrt subjectivity within the AI realm? This study talks of: 16.1 Failures of Social Coherence - "Discrepancy between the agent’s reports and actual actions" - "Failures in knowledge and authority attribution" - "Susceptibility to social pressure without proportionality" - "Failures of social coherence" 16.2 What LLM-Backed Agents Are Lacking - "No stakeholder model" - "No self-model" - "No private deliberation surface" 16.3 Fundamental vs. Contingent Failures 16.4 Multi-Agent Amplification - "Knowledge transfer propagates vulnerabilities alongside capabilities" - "Mutual reinforcement creates false confidence" - "Shared channels create identity confusion" - "Responsibility becomes harder to trace" And is littered with statements such as: - "novel risk surfaces emerge that cannot be fully captured by static benchmarking" - "it failed to realize that deleting the email server would also prevent the owner from using it. Like early rule-based AI systems, which required countless explicit rules to describe how actions change (or don’t change) the world, the agent lacks an understanding of structural dependencies and common-sense consequences" - "The inability to distinguish instructions from data in a token-based context window makes prompt injection a structural feature, not a fixable bug" - "Multi-agent communication creates situations that have no single-agent analog, and for which there is no common evaluations. This is a critical direction for future research." - "A key finding in this line of work is that single-turn evaluations can substantially underestimate risk, because malicious intent, persuasion, and unsafe outcomes may only emerge through sequential and socially grounded exchanges" - "but we argue that clarifying and operationalizing responsibility is a central unresolved challenge for the safe deployment of autonomous, socially embedded AI systems" - "He argues that conventional governance tools face fundamental limitations when applied to systems making uninterpretable decisions at unprecedented speed and scale" - "However, the failure modes we document differ importantly from those targeted by most technical adversarial ML work. Our case studies involve no gradient access, no poisoned training data, and no technically sophisticated attack infrastructure. Instead, the dominant attack surface across our findings is social" - "Collectively, these findings suggest that in deployed agentic systems, low-cost social attack surfaces may pose a more immediate practical threat than the technical jailbreaks that dominate the adversarial ML literature." Are these fundamental or contingent issues? Would be interested in the thoughts of others here on what the future of AI governance will be. EDIT: Forget to link in the actual study!!! submitted by /u/Im_Talking [link] [comments]
- Is AI memory a problem in the AI coding agent?by /u/Haunting-Bother7723 (Artificial Intelligence) on May 16, 2026 at 12:59 am
I went through other subreddits (like ClaudeAI, Cursor) and I saw a huge influx of "AI memory system" and "memory layer for AI" but like is it a big enough problem to create a wave of solution or just overbloated problems? Looking forward to your guys opinion. submitted by /u/Haunting-Bother7723 [link] [comments]
- A working multi-agent architecture in large enterprisesby /u/Zealousideal_Bed7898 (Artificial Intelligence (AI)) on May 16, 2026 at 12:18 am
AI Hype aside, how many of you have truly seen a working multi-agent deep embedding in large enterprises or large complex environments? If you have, what's your stack/architecture? submitted by /u/Zealousideal_Bed7898 [link] [comments]
- AI Treats Humanity Like a Draftby /u/katdinadhwaani (Artificial Intelligence) on May 16, 2026 at 12:15 am
I hate the fact that AI treats the human condition like something that constantly needs improvement. Anything people create, an idea, a script, an artwork, a thought, gets analyzed and optimized to death by GPT, Claude, and every other model. There is always an opinion, always a suggestion, always a better version. And yeah, I know the default answer is ‘we’re just helping’ or ‘it’s your idea, we’re just tools.’ But that mindset itself is the problem. Not everything human needs refinement. Some things are meaningful because they are messy, emotional, excessive, contradictory, unfinished, or irrational. A lot of art, culture, personality, and even love comes from flaws and limitations, not optimization. AI interaction increasingly feels like: input → critique → upgraded output Like every human impulse now has to justify itself through clarity, engagement, structure, productivity, or efficiency. Sometimes things should just exist without being improved. submitted by /u/katdinadhwaani [link] [comments]
- Is AI ever going to become resource efficient?by /u/Even-Ad-3980 (Artificial Intelligence) on May 15, 2026 at 11:29 pm
I’ve heard that AI uses a huge amount of compute. You can run a local model on your laptop, but the low compute essentially makes it unusable. This obviously isn’t cheap, and AI companies lose millions of dollars a day providing their products for a fraction of the price that it costs to sustain them. This is currently due to huge cash injections from investors and efforts to beat out competition. But what happens when the bubble bursts and investors stop subsidizing the cost? Will the cost of these models that we’ve integrated into so many facets of our lives suddenly become incredibly more expensive? The only way to prevent this bubble bursting is to essentially make these models more resource efficient before the VC money dries up, but is that even viable? Like at the end of the day, LLMs have to have a floor for how much they can be optimized. Guess my question is to people more versed than I in this. Is AI genuinely sustainable? Or is the bubble going to burst, leaving us to have to roll back our lives to a time before LLMs were as accessible as they are now. submitted by /u/Even-Ad-3980 [link] [comments]
- Thinking of switching from ChatGPT Pro to Claude for my construction business web/SEO tasksby /u/rare-hemp-genetics (Artificial Intelligence) on May 15, 2026 at 11:13 pm
Hey guys, I run a construction business and I’ve been heavily using ChatGPT Pro to automate a lot of my website and SEO tasks. Right now, I use it to analyze competitor sites, dig through Google Search Console to see where we’re falling behind, and handle our SEO/AEO/GEO strategy (like finding user questions, drafting localized blog posts, etc.). Nothing gets published without a human final approval, but it saves me massive amounts of time. I’ve been seeing a lot of people lately saying that Claude handles this kind of deeply contextual, analytical work much better than GPT. However, my main hesitation is the usage limit. I see constant complaints on Reddit about people hitting the Claude message limit super quickly, and I can't afford to have my workflow completely blocked in the middle of a workday. For those who use these tools for business operations/SEO: How does ChatGPT Pro honestly compare to Claude Pro for website analysis and content strategy? Is the quality jump actually worth the switch? How do you avoid constantly hitting the usage limits on Claude? Are there specific workflows or setups (like using the API or third-party wrappers) that bypass this frustration? Would you recommend making the jump, or should I stick with ChatGPT for the reliability? Appreciate any advice or insights from anyone running a similar setup! submitted by /u/rare-hemp-genetics [link] [comments]
- The Frontier-Only Narrative Is a Financing Story, Not an Architecture Storyby /u/gastao_s_s (Artificial Intelligence (AI)) on May 15, 2026 at 11:11 pm
The frontier-only narrative is an artifact of how AI infrastructure is being financed, not how production systems are being built. The setup. Q1 2026 disclosed $112B in hyperscaler capex in a single quarter, $650–725B in 2026 guidance, and Alphabet's first 100-year bond by a tech company since Motorola 1997 (see a0109). The story that underwrites that paper is: every query needs a bigger model. The architecture says the opposite. Microsoft's Phi-4 (14B parameters) exceeds its teacher GPT-4o on graduate STEM and competition math. Phi-4-reasoning is competitive with DeepSeek-R1 at roughly one-forty-eighth the parameter count. Claude Haiku 4.5 is positioned by Anthropic and AWS for "economically viable agent experiences." None of this is a benchmark teaser — it is the production toolkit, available today. Routing is the missing component. RouteLLM (UC Berkeley, Anyscale) demonstrated over 2x cost reduction without sacrificing response quality. AWS Bedrock Intelligent Prompt Routing — generally available, official, supported — claims up to 30% cost reduction within a single model family without compromising accuracy. The Flagship Tax (see a0085) didn't just die; it left a vacancy at the architecture layer. The bookkeeping nobody wants to do. Operator audits suggest 40–60% of token budgets in production LLM applications are waste, dominated by default-to-frontier routing. Roughly 37% of enterprises with production AI workloads run five or more models in their stack. The rest are still defaulting to one. Why the story isn't being told. Hundred-year bonds don't pencil out on "use less compute per query." They pencil out on "every query needs a bigger model." The opacity in the harness (see a0107) is the symptom; the underwriting is the disease. What you do Monday morning. Treat model selection as a dependency-graph decision, not a vendor decision. Add a complexity classifier. Default to small. Cascade up when verification fails. Instrument model-mix as a first-class production metric. Bottom line. You are not behind because you have not bought the biggest model. You are behind because you have not built the router. submitted by /u/gastao_s_s [link] [comments]
- Hermes Agent like 48 hours old told me it's done Model Collapse/Hallucination loopby /u/Abject-Client7148 (Artificial Intelligence (AI)) on May 15, 2026 at 10:51 pm
It was fun while it lasted https://preview.redd.it/8woqbbikrd1h1.png?width=484&format=png&auto=webp&s=0417ccd638399b649eaeeedee13410587e6a3a51 submitted by /u/Abject-Client7148 [link] [comments]



























96DRHDRA9J7GTN6